Global Health

Three-Class Antiretroviral Therapy for HIV Not Appropriate: Results from the FIRST Study

Rodger MacArthur

RODGER MACARTHUR, Wayne State University, Detroit

REFERENCE: Lancet 2006; 368: 2125-35
A three-class HIV antiretroviral therapy is not necessary, according to data published in the Lancet. The FIRST study had three arms which included non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), or both, all in the presence of nucleoside reverse transcriptase inhibitors. Derek Thorne heard more from Rodger MacArthur of Wayne State University in Detroit.

Similar Interviews

  • Audio Journal of Global Health Issues: Good Adherence to HIV Antiretroviral Therapy in Rural Uganda
  • PAUL WEIDLE, Centers for Disease Control and Prevention, Atlanta REFERENCE: Lancet 2006; 368:1587-94 In rural sub-Saharan Africa there are many barriers to

  • Maraviroc: New Antiretroviral Drug Shows Efficacy and Safety
  • HOWARD MAYER, Pfizer Global Research, New London CT MARK WAINBERG, McGill University, Montreal Abstract Number: 104aLB, 104bLB, 14th Conference on Retroviruses and

  • Entecavir Shows Activity Against HIV But Also Selects for an Antiretroviral Drug Resistance Mutation
  • CHLOE THIO, Johns Hopkins University School of Medicine REFERENCE: Abstract: 136LB, 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles February

    Post a comment

    Subscribe to Audio Medica Podcast